Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback